The Extended Salford Lung Study ("Ex-SLS") Data Access Project
Launched by GLAXOSMITHKLINE · May 12, 2017
Trial Information
Current as of May 25, 2025
Recruiting
Keywords
ClinConnect Summary
The Extended Salford Lung Study (Ex-SLS) is a research project focused on understanding asthma and chronic obstructive pulmonary disease (COPD) better. This study aims to gather more detailed information about patients' health journeys, including their past and future experiences with these conditions. By collecting data from electronic medical records and a short questionnaire, researchers hope to learn more about risks, treatment options, and how these diseases progress over time.
To be eligible for this study, participants must have been part of the original Salford Lung Study and be willing to provide written consent for their additional health information to be collected. The study is open to all adults aged 65 to 74. If you decide to participate, you can expect to share your health history and experiences, which will help improve the understanding of asthma and COPD for everyone. This is an important opportunity not just for researchers but also for patients like you, as it could lead to better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects who were randomized to treatment in the original SLS studies
- • Subjects who are able to, and choose to, provide written consent for the additional information to be collected.
- Exclusion Criteria:
- • Subjects who were lost to follow-up/moved away, withdrew consent or died during or subsequent to the original SLS studies.
- • Subjects considered (at the discretion of the investigator) as too ill to participate or without the mental capacity to provide informed consent.
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manchester, , United Kingdom
Patients applied
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials